Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

• Roland Morley ,

  * E-mail: morley.roland@gene.com

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Alison Cardenas,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Peter Hawkins,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Yasuyo Suzuki,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Virginia Paton,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• See-Chun Phan,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Mark Merchant,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Jessie Hsu,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Wei Yu,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Qi Xia,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Daniel Koralek,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Patricia Luhn,

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯
• Wassim Aldairy

  Affiliation Genentech Inc, South San Francisco, CA, United States of America

  ⨯